Multiple System Atrophy (MSA) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Multiple System Atrophy (MSA) Market is Segmented By Subtype (MSA-Parkinsonian, MSA-Cerebellar), By Diagnosis (Clinical Diagnosis, Biomarker-Based Diagnosis, Imaging-Based Diagnosis), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

Multiple System Atrophy (MSA) Market Leaders

  • Chelsea Therapeutics International, Ltd.
  • Biohaven Pharmaceuticals, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • AstraZeneca plc
  • Theravance Biopharma, Inc.
*Disclaimer: Major players are listed in no particular order.

Multiple System Atrophy (MSA) Market - Company List

  • Chelsea Therapeutics International, Ltd.
  • Biohaven Pharmaceuticals, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • AstraZeneca plc
  • Theravance Biopharma, Inc.
  • Merck & Co.
  • Neuropore Therapies Inc.
  • Newron Pharmaceuticals SpA
  • ProMIS Neurosciences Inc.
  • Stealth BioTherapeutics Corp.
  • AFFiRiS AG
  • Corestem Inc.
  • MitoDys Therapeutics Ltd.
  • Modag GmbH
  • Acadia Pharmaceuticals Inc.
  • Novartis AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson

Multiple System Atrophy (MSA) Market Report Snapshots

Buy Now